Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer

被引：44

作者：

van Weerden, W. M. ^{[1
]}

Bangma, C. ^{[1
]}

de Wit, R. ^{[2
]}

机构：

[1] Erasmus MC, Dept Urol, Josephine Nefkens Inst, NL-3000 CA Rotterdam, Netherlands

[2] Erasmus MC, Dept Med Oncol, NL-3000 CA Rotterdam, Netherlands

来源：

BRITISH JOURNAL OF CANCER | 2009年 / 100卷 / 01期

关键词：

hormone refractory prostate cancer; xenografts; novel therapeutics; PSA biomarker; MITOXANTRONE PLUS PREDNISONE; ANDROGEN RECEPTOR; CELL-LINES; TUMOR-GROWTH; DOUBLE-BLIND; NUDE-MICE; DOCETAXEL; CHEMOTHERAPY; PROGRESSION; SURVIVAL;

D O I：

10.1038/sj.bjc.6604822

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

With docetaxel as effective chemotherapy for hormone refractory prostate cancer (HRPC), the number of new treatment combinations for HRPC is expanding demanding a fast-track screening system. This review elaborates on the use of xenograft models to select the most promising combination therapies for entering into phase II clinical trials.

引用

页码：13 / 18

页数：6

共 34 条

[1] Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients' survival and quality of life [J].

Azim, Hatem A., Jr. ;

Mok, Tony .

ANTI-CANCER DRUGS, 2008, 19 (06) :645-653

[2] Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study [J].

Berthold, Dominik R. ;

Pond, Gregory R. ;

Soban, Freidele ;

de Wit, Ronald ;

Eisenberger, Mario ;

Tannock, Ian F. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) :242-245

[3]

Bosland M C, 1996, Urol Oncol, V2, P99, DOI 10.1016/S1078-1439(96)00077-4

[4] Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy [J].

de Wit, R .

EUROPEAN JOURNAL OF CANCER, 2005, 41 (04) :502-507

[5]

DEWINTER JAR, 1994, AM J PATHOL, V144, P735

[6] Hormone-refractory prostate cancer - Where are we going? [J].

Di Lorenzo, Giuseppe ;

Autorino, Riccardo ;

Figg, William D. ;

De Placido, Sabino .

DRUGS, 2007, 67 (08) :1109-1124

[7] Novel targets and approaches in advanced prostate cancer [J].

Hadaschik, Boris A. ;

Sowery, Richard D. ;

Gleave, Martin E. .

CURRENT OPINION IN UROLOGY, 2007, 17 (03) :182-187

[8] Evolution of the androgen receptor pathway during progression of prostate cancer [J].

Hendriksen, Peter J. M. ;

Dits, Natasja F. J. ;

Kokame, Koichi ;

Veldhoven, Antoine ;

van Weerden, Wytske M. ;

Bangma, Chris H. ;

Trapman, Jan ;

Jenster, Guido .

CANCER RESEARCH, 2006, 66 (10) :5012-5020

[9] Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. [J].

Hermans, Karin G. ;

Bressers, Anke A. ;

van der Korput, Hetty A. ;

Dits, Natasja F. ;

Jenster, Guido ;

Trapman, Jan .

CANCER RESEARCH, 2008, 68 (09) :3094-3098

[10] TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer [J].

Hermans, Karin G. ;

van Marion, Ronald ;

van Dekken, Herman ;

Jenster, Guido ;

van Weerden, Wytske M. ;

Trapman, Jan .

CANCER RESEARCH, 2006, 66 (22) :10658-10663

← 1 2 3 4 →